The field of ovarian cancer research is undergoing a profound transformation, driven by significant advancements in personalized medicine and innovative immunotherapies. As sponsors increasingly target unmet needs with sophisticated treatment modalities, the complexity of conducting large-scale, global clinical studies is escalating. This pivotal era demands a strategic approach to research, emphasizing global collaboration, robust biomarker logistics, and a deep understanding of diverse healthcare landscapes.
Each year, the specter of ovarian cancer continues to affect tens of thousands of women in the United States alone. The American Cancer Society estimates that over 21,000 women will receive a new diagnosis annually, with a tragic toll of more than 12,450 lives lost to the disease. The established first-line treatment protocol typically involves cytoreductive surgery, often a complete hysterectomy, followed by platinum-based chemotherapy. However, a significant challenge persists: the majority of patients are diagnosed at advanced stages, leading to a high incidence of platinum resistance and recurrent disease. The therapeutic options for these patients remain limited, underscoring the urgent need for novel treatment strategies.
Developments and Opportunities in 2026: A Shifting Paradigm
Dr. Edward Dow, MD, a distinguished medical oncologist based in Boston and Global Lead for Solid Tumor Research in Caidya’s oncology and hematology department, observes that the ovarian cancer landscape has witnessed notable progress. Recent FDA approvals have offered new avenues for patients with platinum-resistant ovarian cancer, including pembrolizumab in combination with paclitaxel for PD-L1-positive individuals, and relacorilant in conjunction with nab-paclitaxel. While these approvals represent positive steps forward, Dr. Dow characterizes them as incremental rather than transformative.
"Platinum-refractory ovarian cancer has been a real barrier for a long time," Dr. Dow stated. "The big breakthrough has been mirvetuximab for folate receptor alpha (FRα)-positive platinum refractory ovarian cancer. That was significant, but FRα is only expressed in about 25% of patients. And if you look up the guidelines, it’s doctor’s choice for a second agent, meaning there’s really no standard of care."
This persistent unmet need presents a fertile ground for biotechnology innovators. The development of effective front-line treatments that can reduce relapse rates and prolong progression-free survival is a critical priority. Furthermore, the search for alternative treatment options for platinum-refractory patients continues, with targeted approaches such as antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and oncolytic viruses showing considerable promise.
The growing importance of biomarkers has been another significant development in recent years. While ovarian cancer has historically been considered a heterogeneous disease that was "late to the game" in adopting genomic profiling and personalized treatment strategies, this is rapidly changing. Biomarkers such as BRCA1/2 mutations are now integral to defining genetic subtypes and guiding appropriate treatment paradigms in the initial treatment setting. Concurrently, substantial advancements in FRα research are actively shaping strategies for later lines of therapy.
A Challenging Landscape for Today’s Trials: Escalating Complexity
Analysis from GlobalData highlights a dramatic surge in clinical trial activity. In 2025, a notable 29 Phase III studies were initiated in ovarian cancer, nearly doubling the number from 2024 and representing a 26% increase compared to the previous record year. The first four months of 2026 have already surpassed the total number of new ovarian cancer trials initiated by the end of 2023, with 86 ongoing Phase III trials worldwide and an additional 28 in the planning stages.
This intensified research activity, common across many areas of oncology, has led to a highly competitive environment, particularly in the race to develop novel ADCs and combination therapies. Compounding this competition is the increasing complexity of trial protocols. Many studies now incorporate multiple arms or cohorts to evaluate various treatment combinations, including maintenance cohorts designed to disentangle the effects of therapies like PARP inhibitors from the initial induction regimens. As treatment outcomes improve and expand, trials are increasingly required to measure a broader array of biomarkers and multiple endpoints, necessitating more sophisticated monitoring and complex statistical modeling.
Ovarian cancer, already classified as a rare disease, faces further enrollment challenges as patient stratification and precision biomarker strategies become paramount. This trend often necessitates larger overall sample sizes to ensure statistically meaningful subgroup analyses, making large, multinational studies indispensable.
"It really comes down to being able to find the patients," explained Corey Eisenberg, Director of Clinical Development at Caidya. "You have to go where the patients are, and a lot of the time you are not going to find that in one country, so you need to expand out. At the same time, you need to have an eye for commercial considerations, such as where you intend to market the drug. For instance, some countries have certain rules regarding patient data and the percent of patients required to be enrolled in-country."
Eisenberg further elaborated that broader patient access is intrinsically linked to the design of increasingly global studies, which in turn facilitates wider commercialization opportunities. However, conducting cross-border studies demands meticulous alignment between site feasibility and the sponsor’s ultimate objectives, enabling judicious country selection and more effective patient recruitment.
Global Ovarian Cancer Studies: Benefits and Risks
Dr. Dow identified standard of care fragmentation as another significant hurdle. In low and middle-income countries (LMICs), treatment is frequently limited to surgery and chemotherapy, with even access to paclitaxel being inconsistent in some regions. Advanced maintenance therapies, such as PARP inhibitors, are often unavailable or unaffordable in LMICs, and access to genetic testing for BRCA mutations further exacerbates disparities, impacting the implementation of precision therapy programs.
An additional layer of complexity arises when analyzing data for pharmacogenomic differences. "We have to be very thoughtful about how we combine data from multiple sites across the globe," Dr. Dow emphasized. He referenced a critical learning from lung cancer research, where EGFR mutations in Japanese women were associated with high rates of interstitial lung disease, prompting stringent regulatory oversight from the Japanese PMDA.
Moreover, as competition among sponsors intensifies, a traditional global strategy relying solely on established overseas locations may prove insufficient. Eisenberg suggests that sponsors increasingly need to "think outside the box" when selecting research sites.
"You have to balance the commercial goals with being able to find patients and with navigating the competitive landscape, which means you sometimes have to leave your comfort zone to find the right sites," he stated.
Emerging opportunities include China, with its rebranded NMPA and regulatory approval timelines now comparable to the FDA. Latin America and previously overlooked regions of Eastern and Central Europe also present significant potential.
Expanding the scope of site selection could also involve collaboration with community health practices. Investing in the training of these potential sites could prove to be a critical differentiator for trial success, offering substantial benefits in terms of patient referral rates.
Biomarker Logistics: A Critical Bottleneck
Global studies introduce considerable logistical challenges, particularly with the ascendance of biomarkers. Biomarker testing often exhibits inconsistency across different regions and lines of care. In instances where these tests are not yet integrated into the standard of care, infrastructure gaps can emerge. The availability of standardized, accredited testing facilities can delay or even prevent patient selection.
In certain scenarios, shipping patient samples to a central laboratory in another country might be feasible. However, this approach introduces added logistical complexity and carries the risk of sample degradation and prolonged turnaround times. Furthermore, in countries like China, regulations often prohibit samples from leaving the country, and certain types of samples are also restricted, presenting further complications for global research endeavors.
The assays used for diagnostic testing can also pose a bottleneck, as they ideally need to be standardized across all participating regions. When a novel biomarker is involved, additional time must be allocated for the development of a new assay or companion diagnostic, which can easily extend project timelines beyond initial expectations. While these challenges are not insurmountable, they necessitate meticulous planning and the establishment of a robust centralized team to effectively mitigate risks.
"The quality of who you’re contracting with is paramount to any biomarker-driven study," Dr. Dow affirmed. "They need to have knowledgeable boots on the ground – people with the right expertise, who know the landscape, who can contract with these labs and understand how samples are collected in that region and what kind of assays are used."
The Bottom Line for Ovarian Cancer Research
In the dynamic realm of ovarian cancer research, clinical trial success is increasingly contingent upon a sponsor’s ability to navigate a crowded, rapidly evolving, and operationally complex environment while maintaining a competitive edge. Global studies are no longer optional but essential, demanding rigorous feasibility planning and the engagement of expert Contract Research Organizations (CROs). These CROs must possess the capability to translate intricate protocols and ambitious development plans into practical, executable strategies. This involves incorporating innovative thinking and comprehensive site training to tap into underutilized referral pathways, thereby bolstering patient enrollment.
As the logistical intricacies of modern biomarker-driven ovarian cancer studies continue to escalate, sponsors require CROs with a strategic presence in key regions and localized expertise where it matters most. In this challenging yet promising landscape, Caidya’s integrated team of medical, scientific, and clinical development specialists is positioned to refine global strategies and accelerate the journey from feasibility to market, ultimately contributing to the advancement of ovarian cancer treatment.
Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company. Its investors include entities located in the People’s Republic of China (PRC), and it may be subject to PRC laws and regulations that differ from those of the United States.
Leave a Reply